Sodium aminosalicylate controlled release - AGI Therapeutics
Alternative Names: 4-ASA-Na - AGI Therapeutics; AGI-022Latest Information Update: 04 Nov 2017
At a glance
- Originator AGI Therapeutics
- Class Anti-inflammatories; Antituberculars; Salicylates; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Ulcerative colitis
Highest Development Phases
- No development reported Ulcerative colitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Ulcerative-colitis in Ireland (PO, Controlled release)
- 09 Feb 2009 Clinical development is ongoing in Ireland
- 27 Sep 2007 Clinical development is ongoing